Europe Antibiotics Market Size To Reach $13.7 Billion By 2030

Europe Antibiotics Market Growth & Trends

The Europe antibiotics market size is anticipated to reach USD 13.7 billion by 2030 and is projected to grow at a CAGR of 3.28% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing urbanization and modernization result in people suffering from chronic disorders, which further drives the demand and sales of antibiotics in the region. In addition, the aged population in Europe has been demonstrated to be a primary factor driving the market growth.

The rising infectious diseases among healthcare personnel are prevalent as a result of hospital-acquired illnesses that involve excessive antibiotic usage. Thus, to trail the hospital procedure, the patients are required to stay in hospitals for a longer duration, which is evidenced to be a key reason for hospital-acquired infections and intake of antibiotics.

 Request a free sample copy or view report summary: Europe Antibiotics Market Report

Europe Antibiotics Market Report Highlights

• Based on drug class, the penicillin segment led the market with the largest revenue share of 25% in 2023, owing to its prominent application in treating various diseases, including diseases caused by streptococci, staphylococci, listeria, and clostridium. The cephalosporin segment is expected to grow at the fastest CAGR over the forecast period

• Based on type, the generic antibiotics segment held the market with the largest revenue share of 81.0% in 2023, attributed to the reasonability of generic inventions and a supportive regulatory framework

• Based on type, the branded antibiotics are anticipated to witness at the fastest CAGR over the forecast period, owing to the growing focus of key contributors to emphasize their product roles & distribution network

• Europe dominated the market and held a considerable share in the global antibiotics market owing to factors such as growing numbers of patients with various infections and continuous trials conducted by pharmaceutical businesses

• In September 2020, Shionogi & Co., Ltd. announced that it received FDA approval for a supplemental New Drug Application (sNDA), Fetroja (Cefiderocol). Antibiotics help treat hospital-acquired infectious pneumonia and ventilator-associated infective pneumonia

• In 2023, LifeArc, Medicines Discovery Catapult, and Innovate UK founded PACE (Pathways to Antimicrobial Clinical Efficiency) to fund and support researchers involved in drug and diagnostics development to tackle antimicrobial resistance (AMR)

Europe Antibiotics Market Segmentation

Grand View Research has segmented the Europe antibiotics market report based on drug class, type, action mechanism, and country:

Europe Antibiotics Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Cephalosporin

• Penicillin

• Fluoroquinolone

• Macrolides

• Carbapenems

• Aminoglycosides

• Sulfonamides

• 7-ACA

• Others

Europe Antibiotics Type Outlook (Revenue, USD Million, 2018 - 2030)

• Branded Antibiotics

• Generic Antibiotics

Europe Antibiotics Action Mechanism Outlook (Revenue, USD Million, 2018 - 2030)

• Cell Wall Synthesis Inhibitors

• Protein Synthesis Inhibitors

• DNA Synthesis Inhibitors

• RNA Synthesis Inhibitors

• Mycolic Acid Inhibitors

• Others

Europe Antibiotics Country Outlook (Revenue, USD Million, 2018 - 2030)

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

List of Key Players in the Europe Antibiotics Market

• AbbVie, Inc.

• Pfizer Inc.

• Novartis AG

• Merck & Co., Inc.

• Teva Pharmaceutical Industries Ltd.

• Lupin Pharmaceuticals, Inc.

• Viatris, Inc.

• Melinta Therapeutics LLC

• Cipla, Inc.

• Shionogi & Co., Ltd.

• KYORIN Pharmaceutical Co., Ltd.

• GSK Plc

• Nabriva Therapeutics PLC